Skip to content

CELEROMARKRecalls & reported problems

Hologic, Inc. · CeleroMark Biopsy Site Identification System · Class 2 · Implant

Adverse event reports
2
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 05420045503376), received between Apr 29, 2025 and Dec 22, 2025 — classified as 1 injury, 1 malfunction.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 1 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 1 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1
  • Appropriate Device Problem Term/Code Not Available1

Patient problems

  • Insufficient Information1
  • No Clinical Signs, Symptoms or Conditions1

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionDec 22, 2025Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    IT WAS REPORTED IN A MEDICAL IMAGING CASE LETTER THAT WAS SUBMITTED ON (B)(6) 2020, TO THE JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY THAT, AN ULTRASOUND GUIDED VACUUM ASSISTED EXCISION BIOPSY, WAS PERFORMED ON A 60-YEAR-OLD WOMAN ON AN UNKNOWN DATE, USING A 7G ENCORE PROBE AND ENCOR ENSPIRE BREAST BIOPSY SYSTEM. IT IS REPORTED THAT "A DUMBBELL-SHAPED BREAST BIOPSY MARKER," (B)(6) WAS INSERTED; HOWEVER, "MAMMOGRAPHY SHOWED AN AIR-FILLED CAVITY AT THE LESION SITE, COMPLETE REMOVAL OF THE RESIDUAL LESION/TWIRL MARKER AND THE DUMBBELL-SHAPED BREAST BIOPSY MARKER SEVERAL CENTIMETERS FROM THE SITE." IT WAS FURTHER REPORTED THAT "ANOTHER BREAST BIOPSY MARKER, CYLINDRICAL-SHAPED CELEROMARK WAS PLACED TARGETING THE CAVITY; HOWEVER, INACCURATE POSITIONING/MIGRATION WAS AGAIN SEEN." MALFUNCTION MDR IS BEING SUBMITTED DUE TO THE REPORTED MARKER MIGRATION. HOLOGIC AWARENESS OF THIS CASE LETTER WAS NOVEMBER 24, 2025. NO FURTHER INFORMATION IS CURRENTLY AVAILABLE.

    Patient problems: Insufficient Information

    MAUDE report 23869624 ↗
  • InjuryApr 29, 2025Appropriate Device Problem Term/Code Not Available; Appropriate Device Problem Term/Code Not Available

    IT WAS REPORTED THAT DURING A CELEROMARK PROCEDURE ON (B)(6) 2025, THE PHYSICIAN REPORTED THAT ON THE POST ULTRASOUND GUIDED BREAST BIOPSY THE MARKER COULD BE OBSERVED DEPLOYED. THE PATIENT WAS SENT FOR MAMMOGRAM IN SITU. WHILE REVIEWING THE IMAGE ONLY THE PREVIOUS CLIPS WERE VISIBLE AND THE MARKER COULD NOT BE OBSERVED. PATIENT WAS LATER RECALLED FOR ANOTHER IMPLANTATION AND ANOTHER MARKER. PHYSICIAN REPORTED THAT THE FIRST PROCEDURE WAS A SMALL POCKET OF GAS (¨PSEUDO CLIP¨) WHICH COULD NOT BE DIFFERENTIATED. ANOTHER MARKER WAS IMPLANTED ON A SEPARATE INCISION AND CONFIRMED IMPLANTATION. NO OTHER INFORMATION AVAILABLE.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 21931524 ↗

Other MARKER, RADIOGRAPHIC, IMPLANTABLE devices

All MARKER, RADIOGRAPHIC, IMPLANTABLE devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.